# A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

> **NCT02951767** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 119 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT02951767
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-31
- **Primary completion:** 2016-07-04
- **Final completion:** 2023-02-28
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02951767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02951767, "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT02951767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*